Polypharmacy and high-dose antipsychotic regimes in the community

Psychiatrist

Volumn 34, Issue 2, 2010, Pages 44-46

  Tungaraza, Tongeji E ^a   Gupta, Seema ^b   Jones, Jane ^b   Poole, Rob ^c   Slegg, Gary ^d  

^a Royal Wolverhampton Hospital NHS Trust   (United Kingdom)

^b WREXHAM MAELOR HOSPITAL   (United Kingdom)

^c GLYNDWR UNIVERSITY   (United Kingdom)

^d Wrexham Academic Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; DIAZEPAM; LITHIUM CARBONATE; MOOD STABILIZER; NEUROLEPTIC AGENT; RISPERIDONE; VALPROIC ACID; ZOPICLONE; ZOTEPINE;

ADULT; AFFECTIVE PSYCHOSIS; AGED; ARTICLE; BIPOLAR DISORDER; COMMUNITY CARE; CONTROLLED STUDY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; POLYPHARMACY; SCHIZOAFFECTIVE PSYCHOSIS;

EID: 77951145858     PISSN: 17583209     EISSN: 17583217     Source Type: Journal    
DOI: 10.1192/pb.bp.108.020776     Document Type: Article

References (15)

1. Stahl SM. Antipsychotic polypharmacy. Part 1: Therapeutic option or dirty little secret? J Clin Psychiatry 1999; 60: 425-426
2. Canales PL, Olsen J, Miller AL, Crismon ML. The role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs 1999; 12: 179-188 (Pubitemid 29446503)
3. Lelliott P, Paton C, Harrington M, Konsolaki M, Sensky T, Okocha C. The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatr Bull 2002; 26: 411-414 (Pubitemid 35331237)
4. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2005; 187: 243-247 (Pubitemid 41306105)
5. National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. NICE, 2002.
6. Royal College of Psychiatrists. Consensus Statement on High Dose Antipsychotic Medication (Council Report CR138). Royal College of Psychiatrists, 2006.
7. Barbui C, Nosè M, Mazzi MA, Thornicroft G, Schene A, Becker T, et al. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Pharmacol 2006; 21: 355-362 (Pubitemid 44498277)
8. Jensen B. Antipsychotic comparison chart. RxFiles, 2003 (http://meds. queensu.ca/~clpsych/orientation/Antipschotics%20Comparison%20 Chart.pdf).
9. Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines (8th edn). Taylor & Francis, 2006.
10. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223 (Pubitemid 41345943)
11. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087 (Pubitemid 44498387)
12. Centorrino F, Eakin M, Bahk W, Kelleher JP, Goren J, Salvatore P, et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 2002; 159: 1932-1935
13. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106: 323-330
14. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003; 54: 55-59 (Pubitemid 36043847)
15. Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry 2004; 65: 1597-1600.